Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021 – Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by...

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021 BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...

Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures - Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - BERKELEY...